Myriad Genetics, Inc.
Moat Score — Myriad Genetics, Inc.
Total Moat Score
16 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Decades of hereditary cancer testing have built Myriad one of the largest proprietary genetic variant classification databases in the industry, directly improving the accuracy of tests like MyRisk versus newer entrants that lack this historical depth. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Myriad's scale across Oncology, Women's Health, and Mental Health testing gives it some lab-utilization efficiency, but it competes against similarly scaled national labs (LabCorp, Quest) that can match or beat it on cost for high-volume assays. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Companion-diagnostic ties to specific approved drugs (BRACAnalysis CDx, MyChoice CDx) give Myriad some pricing durability on those tests, but reimbursement-rate pressure from payers across its broader portfolio caps overall pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 3 / 5 | Each additional sample processed sharpens Myriad's variant-classification database, which in turn improves result accuracy and clinical credibility -- a genuine, if slow-compounding, data network effect that newer entrants cannot shortcut. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | EMR integrations, digital-ordering tools, and drug-label-level ties for companion diagnostics create real friction for physicians and biopharma partners to move to a competing lab, though routine hereditary-risk testing remains more switchable than the CDx franchise. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Myriad operates at meaningful scale in hereditary cancer and pharmacogenomic testing, but well-capitalized specialists like Natera and Tempus are expanding into Myriad's core categories simultaneously, showing the space can support multiple scaled competitors rather than naturally consolidating around one. |